logo
  

Renault-Nissan-Mitsubishi Alliance Details New Framework

Renault-Nissan-Mitsubishi outlined a new framework to further reinforce its business model and strengthen its management structure, Renault said Thursday. The new framework was approved at a meeting of the Alliance Operating Board in Yokohama, Japan.

The Alliance operating board has decided that each of the three companies will be the reference company for a region. Nissan for China, Renault for Europe, Mitsubishi for South East Asia.

The board said one company will take the lead in the Alliance for the development of each key technology, which will then be spread among Alliance partners.

On LCV, Renault will develop and manufacture, in Sandouville plant, the Mitsubishi van based on Renault Trafic platform to be sold in the Oceania region.

Strategic Mid-term plans of the three companies will be disclosed simultaneously around May 2020, Renault said.

The Alliance operating board, which consists one chairperson and the chairperson or chief executive officer of each member company, also agreed to engage actively with the respective Board of Directors of Renault, Nissan and Mitsubishi Motors to strengthen its governance to operate effectively for the benefit of each member company.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Longmont Colorado -based Royal Crest Dairy is recalling 2% Chocolate Milk citing the potential to be contaminated with undeclared egg, a known allergen, the U.S. Food and Drug Administration said. The recall involves Farmer's 2% Reduced Fat Chocolate Milk Pints with the code date of AUG-22. ANI Pharmaceuticals, Inc. (ANIP) Monday announced a wider loss for the second quarter, despite a 52 percent surge in revenues. For the full year 2022, the company reiterated the adjusted earnings per share range, revenue guidance and raised Cortrophin revenue outlook. The company reported a quarterly... Shares of BioNTech SE were losing around 4 percent in the morning trading in Germany and around 5 percent in the pre-market activity on Nasdaq after the German Covid-19 vaccine maker reported sharp drop in profit and revenues for the second quarter. However, the company recorded strong growth in first-half results. Further, the company maintained BioNTech COVID-19 vaccine revenue guidance
Follow RTT